Unikon120 mg/5 ml

Unikon 120 mg/5 ml is indicated for the- Control of acute asthma. Management of chronic asthma (For both Symptomatic and prophylactic treatment). For controlling nocturnal asthma and early morning wheezing. Management of chronic obstructive lung disease (Chronic bronchitis and emphysema) and acute exacerbation of chronic obstructive lung disease. Control of apnea of pre-maturity.

Bronchodilator, Unikon 120 mg/5 ml & related drugs

Unikon 120 mg/5 ml is a bronchodilator, structurally classified as a Methylxanthine. Unikon 120 mg/5 ml has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation and suppression of the response of the airways to stimuli. Unikon 120 mg/5 ml also increases the force of contraction of diaphragmatic muscles. The half-life of Unikon 120 mg/5 ml is influenced by a number of known variables. In adult nonsmokers with uncomplicated asthma the half-life ranges from 3 to 9 hours

The dose of Unikon 120 mg/5 ml must be individualized on the basis of peak serum Unikon 120 mg/5 ml concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects. Most of the sustained release preparations may be administered every 12 hours in adults while administration every 8 hours may be necessary in some children with markedly rapid hepaticmetabolism of Unikon 120 mg/5 ml. The recommended maintenance dose within accepted therapeutic range is as follows : 16 years or older: 10 mg/Kg/day (Do not exceed 900 mg/day) 12 years-15 years: 13 mg/Kg/day 9-11 years: 16 mg/Kg/day 1 year-8 years: 24-24 mg/Kg/day 6 months-1 year: 12-18 mg/Kg/day 1-6 months: 10 mg/Kg/day.

The dose of Unikon 120 mg/5 ml must be individualized on the basis of peak serum Unikon 120 mg/5 ml concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects. Most of the sustained release preparations may be administered every 12 hours in adults while administration every 8 hours may be necessary in some children with markedly rapid hepaticmetabolism of Unikon 120 mg/5 ml. The recommended maintenance dose within accepted therapeutic range is as follows : 16 years or older: 10 mg/Kg/day (Do not exceed 900 mg/day) 12 years-15 years: 13 mg/Kg/day 9-11 years: 16 mg/Kg/day 1 year-8 years: 24-24 mg/Kg/day 6 months-1 year: 12-18 mg/Kg/day 1-6 months: 10 mg/Kg/day.

Unikon 120 mg/5 ml should not be used concurrently with other preparations containing xanthine derivatives. The clearance of Unikon 120 mg/5 ml is increased by barbiturates, carbamazepine, lithium, phenytoin, rifampicin and sulphinpyrazone and it may therefore be necessary to increase dosage. On the other hand, the clearance of the drug is reduced by allopurinol, cimetidine, ciprofloxacin, corticosteroids, erythromycin, frusemide, isoprenaline, oral contraceptive and thiabendazole and a reduced dosage may therefore be needed to avoid side effects. Unikon 120 mg/5 ml can potentiate hypokalemia resulting from beta-2-agonist therapy, steroids, diuretics and hypoxia, so serum potassium levels should be monitored in such instances.

Unikon 120 mg/5 ml is contraindicated in patients with hypersensitivity to Unikon 120 mg/5 ml or any other component of the product.

Generally side effects are rare at normal dosage. It may include gastrointestinal discomfort, headache, nausea, insomnia and hypotension. CNS stimulation and diuresis may also occur, especially in children.

It is not known whether Unikon 120 mg/5 ml can cause foetal harm when administered to pregnant woman. Xanthines should be given to a pregnant woman only if clearly needed. Unikon 120 mg/5 ml is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. Serious adverse effects in the infant are unlikely unless the mother has toxic serum Unikon 120 mg/5 ml concentrations.

Careful consideration is needed for various interacting drugs and physiologic conditions that can alter Unikon 120 mg/5 ml clearance. Dosage adjustment is required prior to initiation of Unikon 120 mg/5 ml therapy, prior to increases in Unikon 120 mg/5 ml dose, and during follow up. The dose of Unikon 120 mg/5 ml selected for initiation of therapy should be low and, if tolerated, increased slowly over a period of time.

Keep all medicines out of reach of children. Store in a cool and dry place, protected from light.

Pediatrics use: The clearance of Unikon 120 mg/5 ml is very low in neonates. Careful attention to dosage selection and monitoring of serum Unikon 120 mg/5 ml concentrations are required in pediatric patients.

Bronchodilator, Unikon 120 mg/5 ml & related drugs

Unikon 120 mg/5 ml is a bronchodilator, structurally classified as a Methylxanthine. Unikon 120 mg/5 ml has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation and suppression of the response of the airways to stimuli. Unikon 120 mg/5 ml also increases the force of contraction of diaphragmatic muscles. The half-life of Unikon 120 mg/5 ml is influenced by a number of known variables. In adult nonsmokers with uncomplicated asthma the half-life ranges from 3 to 9 hours

It is not known whether Unikon 120 mg/5 ml can cause foetal harm when administered to pregnant woman. Xanthines should be given to a pregnant woman only if clearly needed. Unikon 120 mg/5 ml is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. Serious adverse effects in the infant are unlikely unless the mother has toxic serum Unikon 120 mg/5 ml concentrations.

Pediatrics use: The clearance of Unikon 120 mg/5 ml is very low in neonates. Careful attention to dosage selection and monitoring of serum Unikon 120 mg/5 ml concentrations are required in pediatric patients.